DGIdb - NIMOTUZUMAB Drug Record

NIMOTUZUMAB chembl:CHEMBL2108359 Antineoplastic

Alternate Names:

HR3

THERACIM-HR3

THERALOC

THERALOC THERACIM

NIMOTUZUMAB

Drug Info:

FDA Approval not approved

Drug Class monoclonal antibody

Drug Indications antineoplastic agent

Drug Class Therapeutic Antibodies

(1 More Sources)

Publications:

Satoh et al., 2015, Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer., Gastric Cancer

NIMOTUZUMAB EGF

Interaction Score: 10.3

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vaccine, EGF cancer

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
NIMOTUZUMAB EGFR

Interaction Score: 0.92

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name Nimotuzumab

PMIDs:
25185971

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB

MyCancerGenome: NIMOTUZUMAB
- Version: 20-Jun-2017
Alternate Names:

H-R3 Development Name

THERACIM Development Name

NIMOTUZUMAB Generic Name

Drug Info:

Drug Class Therapeutic Antibodies

Publications:
TdgClinicalTrial: NIMOTUZUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval not approved

Publications:
JAX-CKB: Nimotuzumab
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Satoh et al., 2015, Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer., Gastric Cancer
TALC: NIMOTUZUMAB
- Version: 12-May-2016
Alternate Names:

NIMOTUZUMAB Primary Drug Name

NIMOTUZUMAB Drug Generic Name

THERACIM H-R3NA Drug Trade Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2108359
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

FDA Approval	not approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
Drug Class	Therapeutic Antibodies

Notes
Novel drug target	Established target
Trial Name	Nimotuzumab

H-R3	Development Name
THERACIM	Development Name
NIMOTUZUMAB	Generic Name

NIMOTUZUMAB	Primary Drug Name
NIMOTUZUMAB	Drug Generic Name
THERACIM H-R3NA	Drug Trade Name

HR3
THERACIM-HR3
THERALOC
THERALOC THERACIM
NIMOTUZUMAB

NIMOTUZUMAB Drug Record

NIMOTUZUMAB chembl:CHEMBL2108359 Antineoplastic

Alternate Names:

Drug Info:

Publications:

NIMOTUZUMAB EGF

Interaction Types & Directionality: n/a

Interaction Info: Trial Name vaccine, EGF cancer Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

NIMOTUZUMAB EGFR

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name Nimotuzumab

PMIDs: 25185971

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB

MyCancerGenome: NIMOTUZUMAB

Alternate Names: H-R3 Development Name THERACIM Development Name NIMOTUZUMAB Generic Name

Drug Info: Drug Class Therapeutic Antibodies

Publications:

TdgClinicalTrial: NIMOTUZUMAB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class monoclonal antibody FDA Approval not approved

Publications:

JAX-CKB: Nimotuzumab

Alternate Names:

Drug Info:

Publications: Satoh et al., 2015, Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer., Gastric Cancer

TALC: NIMOTUZUMAB

Alternate Names: NIMOTUZUMAB Primary Drug Name NIMOTUZUMAB Drug Generic Name THERACIM H-R3NA Drug Trade Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2108359

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vaccine, EGF cancer

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name Nimotuzumab

PMIDs:
25185971

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB

Alternate Names:

H-R3 Development Name

THERACIM Development Name

NIMOTUZUMAB Generic Name

Drug Info:

Drug Class Therapeutic Antibodies

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval not approved

Publications:

Satoh et al., 2015, Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer., Gastric Cancer

Alternate Names:

NIMOTUZUMAB Primary Drug Name

NIMOTUZUMAB Drug Generic Name

THERACIM H-R3NA Drug Trade Name